CJC-1295 (No DAC) vs FLGR-242: Mechanism, Half-Life & Research Use

Direct Comparison: CJC-1295 (No DAC) vs FLGR-242

CJC-1295 (No DAC) and FLGR-242 represent distinct approaches to growth hormone-releasing hormone (GHRH) receptor research. CJC-1295 (No DAC) is a 29-amino acid agonist designed to mimic endogenous GHRH while resisting enzymatic degradation, thereby stimulating pulsatile GH and IGF-1 secretion. In contrast, FLGR-242 is a modified peptide analog utilized in specialized receptor binding and GH axis modulation assays. While CJC-1295 (No DAC) sustains biological signaling across extended physiological windows, FLGR-242 offers targeted kinetics for probing specific receptor interactions.

Preclinical Comparison Criteria Table

The table below outlines key biochemical and experimental parameters comparing CJC-1295 (No DAC) against FLGR-242 for comparative laboratory research.

| Criteria | CJC-1295 (No DAC) | FLGR-242 | |---|---|---| | Primary Receptor Target | GHRH Receptor (GHRHR) | Modified GHRH Receptor / GH Axis Ligand | | Mechanistic Class | Synthetic GHRH Agonist (Tetrasubstituted) | GHRH Peptide Analog / Receptor Probe | | Reported Half-Life (In Vivo/In Vitro) | ~30 minutes (plasmidic/enzymatic resistant) | ~15–45 minutes (assay-dependent) | | Primary Solvents | Bacteriostatic Water, Sterile Water, Dilute Acid | Sterile Water, PBS, Dimethyl Sulfoxide (DMSO) | | Preclinical Research Models | Rodent, In Vitro Pituitary Culture | Cell Culture, Targeted Receptor Binding Assays | | Available Unit Quantities | 2 mg, 5 mg, 10 mg lyophilized vials | 2 mg, 5 mg lyophilized vials |

Researchers analyzing signal transduction pathways can utilize these physical and kinetic baseline metrics when structuring baseline controls across automated liquid handling systems.

Structural Chemistry and Receptor Binding Kinetics of CJC-1295 (No DAC)

CJC-1295 (No DAC), also classified as Tetrasubstituted GRF 1-29, is a synthetic peptide containing four amino acid substitutions relative to native GHRH (1-29). These structural modifications—specifically at positions 2, 8, 15, and 27—protect the peptide chain from rapid cleavage by dipeptidyl peptidase-IV (DPP-IV). By preserving structural integrity at the N-terminal active site, CJC-1295 (No DAC) maintains selective affinity for the GHRH receptor located on pituitary somatotropes.

In vitro binding assays demonstrate that CJC-1295 (No DAC) activates the G-protein coupled GHRH receptor, initiating adenylate cyclase signaling and elevating intracellular cyclic adenosine monophosphate (cAMP). This downstream cascade triggers the synthesis and pulsatile exocytosis of endogenous growth hormone. Preclinical studies suggest that because CJC-1295 (No DAC) lacks the Drug Affinity Complex (DAC) maleimide moiety, it does not bind covalently to circulating serum albumin, resulting in a physiological, pulsatile release profile rather than continuous basal elevation.

FLGR-242: Molecular Structure and Pharmacological Profile

FLGR-242 is an engineered peptide derivative developed to investigate modified binding dynamics within the growth hormone-releasing hormone receptor superfamily. Structurally synthesized to withstand rapid serum clearance relative to native short-chain fragments, FLGR-242 acts as a specific biochemical probe in cell culture systems and competitive displacement studies.

In vitro characterization indicates that FLGR-242 exhibits distinct binding kinetics compared to standardized GHRH agonists. While tetrasubstituted analogs prioritize maximum agonist activity and extended intracellular cAMP accumulation, FLGR-242 is typically employed to investigate receptor binding pocket dynamics, antagonist/partial agonist kinetics, or localized tissue responsiveness. Rodent tissue assays demonstrate its utility in mapping receptor distribution without inducing the systemic IGF-1 amplification seen with full-spectrum GHRH agonists.

Differential Growth Hormone Axis Modulation in Preclinical Models

The primary functional difference between these two compounds lies in their modulation of the somatotropic axis. CJC-1295 (No DAC) acts as a robust GHRH analog, studied extensively as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. Animal models evaluated with CJC-1295 (No DAC) demonstrate enhanced nitrogen retention, cellular proliferation, and extracellular matrix remodeling due to elevated systemic insulin-like growth factor 1 (IGF-1).

Conversely, FLGR-242 provides a specialized tool for isolated bioassays where sustained systemic IGF-1 elevation is not the primary experimental objective. In comparative pituitary cell cultures, CJC-1295 (No DAC) stimulates robust GH mRNA expression and protein release, whereas FLGR-242 allows investigators to analyze receptor-level saturation limits and ligand-receptor interaction kinetics without trigger-heavy downstream endocrine cascades. This renders FLGR-242 valuable for baseline ligand displacement assays.

Comparative Pharmacodynamics and Half-Life Profiles

Pharmacokinetic evaluations reveal substantial differences in physiological persistence between these peptides. Native GHRH (1-29) possesses an in vivo half-life of less than 7 minutes due to swift DPP-IV cleavage between Tyr1 and Ala2. The four amino acid substitutions in CJC-1295 (No DAC) extend its biological half-life to approximately 30 minutes in rodent plasma models, permitting sufficient receptor interaction time to initiate natural GH release cycles without altering systemic binding proteins.

FLGR-242 exhibits a variable clearance profile depending on the matrix and model system employed. In cell-free enzymatic stability assays, FLGR-242 shows moderate resistance to proteolytic degradation. However, in whole-blood or tissue homogenate models, its clearance rate typically falls between 15 and 45 minutes. Unlike CJC-1295 with DAC (which forms covalent bonds with albumin to achieve a multi-day half-life), both CJC-1295 (No DAC) and FLGR-242 clearance curves allow researchers precise temporal control over experimental exposures.

Topical Cluster Analysis: GHRH Analogs and Secretagogue Classes

To contextualize the comparative efficacy of CJC-1295 (No DAC) and FLGR-242, researchers frequently cross-reference other compounds within the broader GHRH and GH secretagogue categories available in our catalog of all peptides. Native sequence fragments such as Sermorelin represent the shortest functional GHRH sequence (GRF 1-29), exhibiting a short half-life suited for rapid acute release studies. Modified versions like Mod GRF 1-29 share identical amino acid substitutions with CJC-1295 (No DAC), rendering the terms functionally synonymous in contemporary literature.

When research designs require dual-receptor co-activation, GHRH agonists are often paired with ghrelin receptor (GHSR-1a) agonists such as Ipamorelin. While GHRH analogs like CJC-1295 (No DAC) initiate cyclic AMP signaling, ghrelin secretagogues trigger intracellular calcium influx, creating a synergistic pulse profile in dual-agent preclinical models. FLGR-242 serves a distinct analytical niche, providing a baseline comparison compound when evaluating these potent synergistic secretagogue pairs.

Study Design Selection: Matching the Compound to Research Objectives

Selecting between CJC-1295 (No DAC) and FLGR-242 depends directly on the primary hypothesis and analytical parameters of the study design.

CJC-1295 (No DAC) is optimal for: - Preclinical models investigating skeletal muscle regeneration, tendon healing, or cellular repair mediated by elevated IGF-1. - Pituitary secretion studies measuring physiological GH pulse amplitude and baseline somatotrope responsiveness. - Long-term cell culture studies where DPP-IV resistance is required to maintain peptide activity in serum-containing media.

FLGR-242 is optimal for: - Competitive ligand-binding assays evaluating GHRH receptor occupancy and binding site kinetics. - Studies isolating receptor activation from secondary systemic metabolic cascades. - In vitro assays requiring precise baseline comparative metrics against modified GHRH sequences.

Laboratory Reconstitution and Handling Best Practices

Both CJC-1295 (No DAC) and FLGR-242 are supplied as lyophilized cakes to ensure maximal chemical stability during transport and storage. Upon receipt, lyophilized vials should be stored at -20°C or -80°C for long-term preservation.

For reconstitution, bring the vial to room temperature prior to introducing solvent to prevent condensation within the matrix. Reconstitute using sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory protocols or Sterile Normal Saline for immediate cell culture applications. Slowly stream the solvent down the inner glass wall of the vial rather than directing it onto the lyophilized powder. Allow the powder to dissolve completely through gentle swirling; never vortex reconstituted peptide solutions. For exact molar calculations, volumetric dilutions, and liquid chromatography preparation, consult our online reconstitution calculator.

Quality Assurance and Analytical Standard Verification

Reproducibility in peptide research requires stringent chemical verification. Impurities or structural truncated sequences can alter receptor binding affinity, compromise assay validity, and introduce confounding data in sensitive cell models. PX1 Research subjects every synthesis lot to rigorous quality control standards in ISO 17025 accredited facilities located in the United States.

Each batch of CJC-1295 (No DAC) and FLGR-242 undergoes High-Performance Liquid Chromatography (HPLC) to verify chemical purity (>98%) and Mass Spectrometry (MS) to confirm exact molecular weight. Furthermore, routine chromogenic LAL assays ensure low endotoxin levels (<0.01 EU/mg), making these reagents suitable for delicate cellular and in vivo research protocols. Investigators can access lot-specific documentation directly via our Certificate of Analysis (COA) portal. Detailed protocol guidance and bulk laboratory ordering options are also available through our wholesale research account portal.